680 related articles for article (PubMed ID: 19112166)
1. Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial.
Després JP; Ross R; Boka G; Alméras N; Lemieux I;
Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):416-23. PubMed ID: 19112166
[TBL] [Abstract][Full Text] [Related]
2. ADAGIO-Lipids gives promises but faces the setbacks.
Taskinen MR
Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):339-40. PubMed ID: 19228609
[No Abstract] [Full Text] [Related]
3. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
Després JP; Golay A; Sjöström L;
N Engl J Med; 2005 Nov; 353(20):2121-34. PubMed ID: 16291982
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
5. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.
Pi-Sunyer FX; Aronne LJ; Heshmati HM; Devin J; Rosenstock J;
JAMA; 2006 Feb; 295(7):761-75. PubMed ID: 16478899
[TBL] [Abstract][Full Text] [Related]
6. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
Scheen AJ
J Neuroendocrinol; 2008 May; 20 Suppl 1():139-46. PubMed ID: 18426513
[TBL] [Abstract][Full Text] [Related]
7. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.
Van Gaal LF; Scheen AJ; Rissanen AM; Rössner S; Hanotin C; Ziegler O;
Eur Heart J; 2008 Jul; 29(14):1761-71. PubMed ID: 18417461
[TBL] [Abstract][Full Text] [Related]
8. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity.
Christopoulou FD; Kiortsis DN
J Clin Pharm Ther; 2011 Feb; 36(1):10-8. PubMed ID: 21198716
[TBL] [Abstract][Full Text] [Related]
9. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.
Hollander P
Am J Med; 2007 Feb; 120(2 Suppl 1):S18-28; discussion S29-32. PubMed ID: 17296341
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.
Van Gaal L; Pi-Sunyer X; Després JP; McCarthy C; Scheen A
Diabetes Care; 2008 Feb; 31 Suppl 2():S229-40. PubMed ID: 18227491
[TBL] [Abstract][Full Text] [Related]
11. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile.
Poirier B; Bidouard JP; Cadrouvele C; Marniquet X; Staels B; O'Connor SE; Janiak P; Herbert JM
Diabetes Obes Metab; 2005 Jan; 7(1):65-72. PubMed ID: 15642077
[TBL] [Abstract][Full Text] [Related]
12. The metabolic basis of atherogenic dyslipidemia.
Vinik AI
Clin Cornerstone; 2005; 7(2-3):27-35. PubMed ID: 16473258
[TBL] [Abstract][Full Text] [Related]
13. Visceral and not subcutaneous abdominal adiposity reduction drives the benefits of a 1-year lifestyle modification program.
Borel AL; Nazare JA; Smith J; Alméras N; Tremblay A; Bergeron J; Poirier P; Després JP
Obesity (Silver Spring); 2012 Jun; 20(6):1223-33. PubMed ID: 22262155
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular disease under the influence of excess visceral fat.
Després JP
Crit Pathw Cardiol; 2007 Jun; 6(2):51-9. PubMed ID: 17667865
[TBL] [Abstract][Full Text] [Related]
15. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.
Van Gaal LF; Rissanen AM; Scheen AJ; Ziegler O; Rössner S;
Lancet; 2005 Apr 16-22; 365(9468):1389-97. PubMed ID: 15836887
[TBL] [Abstract][Full Text] [Related]
16. Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results.
Ruilope LM; Després JP; Scheen A; Pi-Sunyer X; Mancia G; Zanchetti A; Van Gaal L
J Hypertens; 2008 Feb; 26(2):357-67. PubMed ID: 18192851
[TBL] [Abstract][Full Text] [Related]
17. Pleiotropic effects of rimonabant: clinical implications.
Després JP
Curr Pharm Des; 2009; 15(5):553-70. PubMed ID: 19199981
[TBL] [Abstract][Full Text] [Related]
18. Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?
Di Marzo V
Nat Clin Pract Cardiovasc Med; 2008 Oct; 5(10):610-2. PubMed ID: 18695695
[No Abstract] [Full Text] [Related]
19. Rimonabant.
Henness S; Robinson DM; Lyseng-Williamson KA
Drugs; 2006; 66(16):2109-19; discussion 2120-1. PubMed ID: 17112304
[TBL] [Abstract][Full Text] [Related]
20. The central cannabinoid CB1 receptor is required for diet-induced obesity and rimonabant's antiobesity effects in mice.
Pang Z; Wu NN; Zhao W; Chain DC; Schaffer E; Zhang X; Yamdagni P; Palejwala VA; Fan C; Favara SG; Dressler HM; Economides KD; Weinstock D; Cavallo JS; Naimi S; Galzin AM; Guillot E; Pruniaux MP; Tocci MJ; Polites HG
Obesity (Silver Spring); 2011 Oct; 19(10):1923-34. PubMed ID: 21799481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
